-0.17%
1.88%
-0.33%
-12.03%
15.17%
346.78%
494.81%
AI Spotlight on CAMX
Company Description
Camurus AB (publ), a pharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, Japan, and internationally.The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence; episil oral liquid, a medical device for the treatment of inflammatory and painful conditions in the oral cavity; and Brixadi to treat opioid use disorder Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud's phenomenon.In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; CAM2047 for the treatment of chemotherapy-induced nausea and vomiting that is in phase 1 clinical trial; and CAM2048, which is in phase I clinical trial for postoperative pain.
Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.
Market Data
| Last Price | 596 |
| Change Percentage | -0.17% |
| Open | 599.5 |
| Previous Close | 597 |
| Market Cap ( Millions) | 35092 |
| Volume | 72252 |
| Year High | 715 |
| Year Low | 417.4 |
| M A 50 | 570.33 |
| M A 200 | 604.2 |
Financial Ratios
| FCF Yield | 0.86% |
| Dividend Yield | 0.00% |
| ROE | 10.46% |
| Debt / Equity | 0.59% |
| Net Debt / EBIDTA | -792.40% |
| Price To Book | 11.23 |
| Price Earnings Ratio | 131.31 |
| Price To FCF | 115.86 |
| Price To sales | 20.78 |
| EV / EBITDA | 93.82 |
News
- Nov -09 - Camurus AB (CAMRF) Q3 2024 Earnings Call Highlights: Record Profit and Revenue Growth Amid ...
- Jul -16 - Camurus reports positive results from Phase III trial of acromegaly treatment
- Jul -15 - Camurus announces positive Phase 3 results from the ACROINNOVA 2 study of octreotide SC depot (CAM2029) in acromegaly patients
- Jun -25 - New publication shows effectiveness data for weekly and monthly buprenorphine injections in treating opioid dependence in individuals using fentanyl
- Jul -17 - Camurus announces new Phase 3 data reinforcing long-term safety and efficacy of octreotide SC depot (CAM2029) in patients with acromegaly
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Pharmaceutical
Expected Growth : 9.08 %
What the company do ?
Camurus AB (publ) is a Swedish pharmaceutical company that develops and commercializes innovative, evidence-based medicines for the treatment of serious and chronic diseases.
Why we expect these perspectives ?
Camurus AB's 9.08% growth is driven by increasing demand for its innovative injectable drugs, particularly in the treatment of opioid dependence and cancer. Strong sales of its lead product, Buvidal, and expansion into new markets, such as the US, contribute to the company's growth momentum.
Camurus Ab (Publ) Products
| Product Range | What is it ? |
|---|---|
| Episil | A prescription medicine used to treat episodic breakthrough pain in adults with cancer who have developed tolerance to opioid medications. |
| Buvidal | A weekly and monthly depot injection for the treatment of opioid dependence. |
| Intermezzo | A sublingual tablet for the treatment of middle-of-the-night awakenings. |
Camurus AB (publ)'s Porter Forces
Threat Of Substitutes
Camurus AB (publ) has a moderate threat of substitutes due to the availability of alternative treatments for opioid dependence and chronic pain management.
Bargaining Power Of Customers
Camurus AB (publ) has a low bargaining power of customers due to the specialized nature of its products and the lack of alternative suppliers.
Bargaining Power Of Suppliers
Camurus AB (publ) has a moderate bargaining power of suppliers due to the presence of multiple suppliers for its raw materials and the company's dependence on a few key suppliers.
Threat Of New Entrants
Camurus AB (publ) has a low threat of new entrants due to the high barriers to entry in the pharmaceutical industry, including regulatory hurdles and the need for significant investment in research and development.
Intensity Of Rivalry
Camurus AB (publ) operates in a highly competitive industry with several established players, leading to a high intensity of rivalry.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 1.61% |
| Debt Cost | 6.62% |
| Equity Weight | 98.39% |
| Equity Cost | 8.20% |
| WACC | 8.17% |
| Leverage | 1.64% |
Camurus AB (publ) : Quality Control
Camurus AB (publ) passed 8 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| ROVI.MC | Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, production, and sale of pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company distributes other products that are … |
| ZEAL.CO | Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, … |
| ALK-B.CO | ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. It product portfolio include GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDACURE, and ITULAZAX for treatment of allergic rhinitis … |
| ALKS | Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its … |
| GMAB.CO | Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Rovi
A-Score
1-Year Total Return ->
🥈
ALK-Abelló
A-Score
1-Year Total Return ->
🥉
Genmab
A-Score
1-Year Total Return ->
4
Camurus
A-Score
1-Year Total Return ->
5
Alkermes
A-Score
1-Year Total Return ->
6
